ACO Name and Location 

North Texas CIN, Inc 
17300 Dallas Parkway 
Suite 3010 
Dallas, Texas 75248 

ACO Primary Contact 

Primary Contact Name 

John Moore, MD 

Primary Contact Phone Number 

469-523-1090 

Primary Contact Email Address 

Organizational Information 

ACO participants: 

ACO Participants 

ACO Participant in Joint Venture (Enter Y or N) 

Charles Kasbarian 

Y 

FAMILY ORTHOPEDICS AND REHABILITATION LLP 

Y 

Brenda J Hampton MD PA 

Y 

Myint & Horton, P.A. 

Y 

Vijaya Nama MD PA. 

Y 

786 MEDICAL PLLC 

Y 

ERS Medical Associates of Denton 

Y 

Brett L. Cochrum, MD, PA 

Y 

THOC PA 

Y 

OFFICES OF FAMILY MEDICINE PLLC 

Y 

AULT MCINNIS PLLC 

Y 

Chuling Jiang, MD 

Y 

Charles Safely 

Y 

Seema Kazi MD PA 

Y 

David Maldonado III MD PA 

Y 

OMEGA HEIGHTS FAMILY MEDICINE CLINIC PLLC 

Y 

Internal Medicine Associates of Texas 

Y 

David W Carlson MD PA 

Y 

James R Long MD PA 

Y 

Douglas C. Smith, M.D., P.A. 

Y 

JAMES R LOW, JR., M.D.,P.A. 

Y 

CENTER FOR FAMILY MEDICINE,PA 

Y 

Charles Kasbarian, MD 

Y 

Charles Safely 

Y 

ABILENE INTERNIST AND ASSOCIATES PA 

Y 

VIRGINIA STARK-VANCE, M.D., P.A. 

Y 

Tarrant County CArdiology PA 

Y 

DR. SAMUEL C. LEE, PA 

Y 

MEDI CARE CLINICS PLLC 

Y 

 

 

 

ACO governing body: 

Member 

Member’s Voting Power 

Membership Type 

ACO Participant TIN Legal Business Name/DBA, if Applicable 

Last Name 

First Name 

Title/Position 

Moore 

John 

Chair 

 11.11% 

Non-ACO Participant  

 

Lee 

Samuel 

 

 

11.11% 

ACO Participant  

DR. SAMUEL C. LEE, PA 

Culpepper 

Guy 

 

 

11.11% 

Non-ACO Participant  

 

Linden 

Benjamin 

 

 

11.11% 

Non-ACO Participant  

 

Flowers 

John 

 

 

11.11% 

Medicare Beneficiary Representative 

 

Gramer 

Jill 

 

 

11.11% 

Non-ACO Participant 

 

Selod 

Faroq 

 

 

11.11% 

Non-ACO Participant 

 

Schwartz 

Mike 

 

 

11.11% 

Non-ACO Participant 

 

Bret 

Bob 

 

 

11.11% 

Non-ACO Participant  

 

 

 

Key ACO clinical and administrative leadership: 

John Moore 

ACO Executive 

Samuel Lee, DO 

Medical Director 

Mr. David DeYoung 

Compliance Officer 

Brian Casstevens, RN 

Quality Assurance/Improvement Officer 

 

 

 

 

Associated committees and committee leadership: 

Committee Name 

Committee Leader Name and Position 

Quality Improvement Care Coordination Committee  

Brian Casstevens, RN  

Compliance Committee  

David DeYoung, Chair 

 

 

Types of ACO participants, or combinations of participants, that formed the ACO: 

  • Networks of individual practices of ACO professionals 

 

Shared Savings and Losses 

Amount of Shared Savings/Losses 

  • N/A 

 

Shared Savings Distribution 

  • N/A  

Quality Performance Results 

2016 Quality Performance Results: 

ACO# 

Measure Name 

Rate 

ACO Mean 

ACO-1 

CAHPS: Getting Timely Care, Appointments, and Information  

N/A 

80.51 

ACO-2 

CAHPS: How Well Your Providers Communicate  

N/A 

93.01 

ACO-3 

CAHPS: Patients’ Rating of Provider  

N/A 

92.25 

ACO-4 

CAHPS: Access to Specialists  

N/A 

83.49 

ACO-5 

CAHPS: Health Promotion and Education 

N/A 

60.32 

ACO-6 

CAHPS: Shared Decision Making  

N/A 

75.40 

ACO-7 

CAHPS: Health Status/Functional Status  

N/A 

72.30 

ACO-34 

CAHPS: Stewardship of Patient Resources  

N/A 

26.97 

ACO-8 

Risk Standardized, All Condition Readmission 

N/A 

14.70 

ACO-35 

Skilled Nursing Facility 30-day All-Cause Readmission measure (SNFRM) 

N/A 

18.17 

ACO-36 

All-Cause Unplanned Admissions for Patients with Diabetes 

N/A 

53.20 

ACO-37 

All-Cause Unplanned Admissions for Patients with Heart Failure 

N/A 

75.23 

ACO-38 

All-Cause Unplanned Admissions for Patients with Multiple Chronic Conditions 

N/A 

59.81 

ACO-9 

Ambulatory Sensitive Condition Admissions: Chronic Obstructive Pulmonary Disease or Asthma in Older Adults (AHRQ Prevention Quality Indicator (PQI) #5) 

N/A 

9.27 

ACO-10 

Ambulatory Sensitive Conditions Admissions: Heart Failure (AHRQ Prevention Quality Indicator (PQI) #8) 

N/A 

14.53 

ACO-11 

Percent of PCPs who Successfully Meet Meaningful Use Requirements 

N/A 

82.72 

ACO-39 

Documentation of Current Medications in the Medical Record 

N/A 

87.54 

ACO-13 

Falls: Screening for Future Fall Risk  

N/A 

64.04 

ACO-14 

Preventive Care and Screening: Influenza Immunization 

N/A 

68.32 

ACO-15 

Pneumonia Vaccination Status for Older Adults 

N/A 

69.21 

ACO-16 

Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up 

N/A 

74.45 

ACO-17 

Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention 

N/A 

90.98 

ACO-18 

Preventive Care and Screening: Screening for Clinical Depression and Follow-up Plan 

N/A 

53.63 

ACO-19 

Colorectal Cancer Screening 

N/A 

61.52 

ACO-20 

Breast Cancer Screening 

N/A 

67.61 

ACO-21 

Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented  

N/A 

76.79 

ACO-42 

Statin therapy for the Prevention and Treatment of Cardiovascular Disease 

N/A 

77.72 

ACO-27 

Diabetes Mellitus: Hemoglobin A1c Poor Control  

N/A 

18.24 

ACO-41 

Diabetes: Eye Exam 

N/A 

44.94 

ACO-28 

Hypertension (HTN): Controlling High Blood Pressure  

N/A 

70.69 

ACO-30 

Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic 

N/A 

85.05 

ACO-31 

Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) 

N/A 

88.67 

ACO-33 

Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy – for patients with CAD and Diabetes or Left Ventricular Systolic Dysfunction (LVEF<40%) 

N/A 

79.67 

 

 

Payment Rule Waivers 

  • No, our ACO does not use the SNF 3-Day Rule Waiver. 

    Bitnami